Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 13 recruiting now early-phase tilt #119 of 28,707 conditions

Hepatitis C: early-phase trial registry

13 of 108 indexed Hepatitis C trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #119 of 28,707 conditions by registered trial count.

108 US clinical trials · 13 currently recruiting · #119 of 28,707 conditions by registered trial count

Hepatitis C: 108 US clinical trials tracked, 13 recruiting.

Hepatitis C is the subject of 108 registered US clinical trials on ClinicalTrials.gov, 13 of them currently open to new participants. 21 are in Phase 3-4 (later-stage) and 37 in Phase 1-2 (earlier-stage). The most active sponsor is Gilead Sciences, running 7 of these trials.

Enrollment posture brief

Registry condition hepatitis-c

OPEN 13 | RECR 12% | LATE 21 | EARLY 37 | RANK #119 | SPON 7

Nearest open-share peer: HIV Infection (12% recruiting · 74 trials)

Breast Carcinoma58.9%Non-Hodgkin Lymphoma54.2%Quality of Life40.4%Advanced Malignant Solid Neo24.8%Hepatitis C (this)12%
Open-enrollment share among volume-matched conditions near Hepatitis C

Hepatitis C lists 13 open slots (12% of 108 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Hepatitis C on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Hepatitis C is recruiting below its size-band peers.

    13 of 108 indexed trials (12%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Hepatitis C trials is spread across many organizations.

    Gilead Sciences accounts for 7 of 108 trials (6.5%). 67 distinct sponsors appear on at least one study for this condition label.

  3. Typical Hepatitis C enrolment sits around 115 participants.

    Median target enrolment is 115 among the 107 trials that report a genuine target (sentinel values excluded). 49 of those (45.8%) plan for fewer than 100 participants.

  4. Hepatitis C research is mostly interventional.

    86 interventional and 22 observational studies make up this index (79.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 114Phase 223Phase 311Phase 410

Phase Distribution

PhaseTrial count
Phase 1 14
Phase 2 23
Phase 3 11
Phase 4 10

Named interventions

Most-linked intervention names on Hepatitis C records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Ribavirin Drug
10 trials
Placebo Drug
10 trials
RBV Drug
4 trials
Peginterferon alfa-2a Drug
3 trials
Daclatasvir Drug
3 trials
Sofosbuvir Drug
3 trials
sofosbuvir/velpatasvir Drug
3 trials
TD-6450 Drug
2 trials

US sites by state

Facility locations filed on Hepatitis C trials. A trial with sites in several states counts in each.

California 34 trials
New York 31 trials
Texas 29 trials
Florida 25 trials
Maryland 24 trials
Colorado 22 trials
Georgia 18 trials
Illinois 17 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Hepatitis C page

108 registered trials, 13 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hepatitis C condition card totals 108 registered trials; most-linked intervention Ribavirin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.